← boardnext 2027-03next 2027-06next 2027-06
FDMT
4D Molecular Therapeuticsdistress 5/10 · elevated risk$10.52-4%today-21% from 52w high
Rare / Genetic 2
Lead: wet AMD
Revenue
pre-revenue
Liquidity
$458M
Runway
3.5 yrs
Shares 1y
+87%
Price & events
+30.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.0%
1D
-3.0%
1W
-9.3%
1M
+9.5%
3M
+32.2%
6M
+123.4%
1Y
-41.4%
2Y
-57.2%
5Y
-72.1%
All
Overview
- Market Cap
- $523.67M
- Volume
- 44.71K
- 52 Week Range
- $4.16 – $13.30
- Total Shares
- 49.78M
- Float Shares
- 39.01M
- Short %
- 29.42%
- % Held by Insiders
- 3.32%
- % Held by Institutions
- 98.36%
- RVOL
- 0.05x
- Beta
- 2.69
Pipeline stages · 5 programs
4D-150 IVT, Aflibercept IVT
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
4D-710
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
4D-125 IVT Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
4D-310
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 1/2 | 4D-150 IVT, Aflibercept IVTrmat | Neovascular (Wet) Age-Related Macular Degeneration | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | 4D-710 | Cystic Fibrosis Lung | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Macular Neovascularization Secondary to Age-Related Macular Degeneration | — | active not recruiting |
| 2028-11 Estimated 50% readout ~2029-01-15 | Phase 3 | 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Neovascular Age-Related Macular Degeneration (nAMD) | — | recruiting |
| 2029-02-28 Estimated 50% readout ~2029-04-14 | Phase 2 | 4D-150 IVT, Aflibercept IVTrmat | Diabetic Macular Edema, Diabetic Retinopathy | — | active not recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 1/2 | 4D-125 IVT Injection | X-Linked Retinitis Pigmentosa | 21 | active not recruiting |
| 2026-06 | Phase 1/2 | 4D-310 | Fabry Disease | 18 | recruiting |
| 2026-01 | Phase 1/2 | 4D-310 | Fabry Disease | 18 | active not recruiting |
Catalyst news & presentations · 17
- second half of 2027Guided 55%readoutPhase 34D-150 · 52-week topline data from 4FRONT-2SEC 8-K
- H1 2027Guided 55%readoutPhase 34D-150 · Disclose topline data for 4FRONT-1SEC 8-K
- H2 2026Guided 55%enrollment completesecondaryPhase 34D-150 · Complete enrollment of 4FRONT-2SEC 8-K
- 2026-08-10earningsEarningsEarnings releaseyahoo
- Q1 2026enrollment completesecondaryPhase 34D-150 · Complete enrollment of 4FRONT-1SEC 8-K
- Q4 2025readoutPhase 1/24D-150 · Two-year Phase 1/2a and 18-month Phase 2b PRISM dataSEC 8-K
- Q3 2025trial initiationsecondaryPhase 34D-150 · Initiation of 4FRONT-2 Phase 3 trialSEC 8-K
- mid-2025conferencedata presentationsecondaryPhase 14D-150 · 52-week interim data update from SPECTRA at a scientific conferenceSEC 8-K
- mid-2025conferencedata presentationsecondaryPhase 14D-710 · Interim data update at a scientific conferenceSEC 8-K
- H1 2025enrollment completesecondaryPhase 14D-710 · Completion of Phase 1 AEROW enrollmentSEC 8-K
- Q1 2025trial initiationsecondaryPhase 34D-150 · Initiation of 4FRONT-1 Phase 3 trialSEC 8-K
- February 2025readoutPhase 24D-150 · 52-week landmark data for Dose Expansion and Population Extension cohortsSEC 8-K
- 2025-01-10trial discontinued4D-125 · Development terminated for X-linked retinitis pigmentosaSEC 8-K
- 2025-01-10trial discontinued4D-110 · Development terminated for choroideremiaSEC 8-K
- 2025-01-10fda agreement4D-150 · FDA aligned that single Phase 3 trial for DME combined with wet AMD data acceptable for BLA; selected 3E10 vg/eye doseSEC 8-K
- fourth quarter of 2024readoutPhase 24D-150 · Initial 24-week landmark analysis from SPECTRA Dose Confirmation cohortSEC 8-K
- September 2024readoutPhase 34D-150 · Phase 3 trial design announcementSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $28 (+168% upside) · 9 analysts
- 2026-07-20HC Wainwright & Co.Buy
- 2026-03-20HC Wainwright & Co.Buy
- 2026-03-19RBC CapitalOutperform
- 2026-03-19Chardan CapitalBuy
- 2026-01-28BarclaysOverweight
- 2025-12-18Chardan CapitalBuy
Competitors — wet AMD
Recent news
- 2026-07-224D Molecular releases phase 2 data for wet AMD asset 4D-150 - MSN
- 2026-07-214D Molecular Therapeutics (FDMT) Reports Positive Phase 2 Results for AMD Treatment - GuruFocus
- 2026-07-214D Molecular Therapeutics Reports 2-Year Durability Data for 4D-150 in Wet AMD - The Clinical Trial Vanguard
- 2026-07-214D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD - Bitget
- 2026-07-204D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity (FDMT) - Seeking Alpha
- 2026-07-204D Molecular Therapeutics (FDMT) Reports Positive Phase 2 Results for AMD Treatment - GuruFocus
- 2026-07-20Why Is 4D Molecular Therapeutics Stock Gaining Monday? - 4D Molecular Therapeutics (NASDAQ:FDMT) - Benzinga
- 2026-07-204D Molecular Therapeutics Reports Positive 2-Year Phase 2b Results for 4D-150 in Wet AMD, Shows Reduced Treatment Burden and Strong Safety Profile 5678 – Minichart - Minichart
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.